Social Media Ideas for Astrazeneca

AstraZeneca PLC (AZN) Q2 2026 Earnings Call Transcript

AstraZeneca holds talks with Bristol Myers Squibb over £300bn merger

A deal by AstraZeneca chief executive Sir Pascal Soriot would extend the drugmaker's footprint in the US market.

AstraZeneca plots £300bn tie-up with US rival

<![CDATA[AstraZeneca and Bristol Myers Squibb Held Merger Talks: Report]]>

<![CDATA[Everything You Need to Know About the AstraZeneca–Bristol Myers Squibb Merger Rumors]]>

AstraZeneca shares soar amid strong demand for cancer treatments

Revenues for the first half rose 6% to £23bn while profits rose 2% to £5bn. Chief exec Pascal Soriot, pictured, pointed to booming sales of specific canc

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling• AstraZeneca shares fall 8.9% over merger talks with US cancer drug firmS...

AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm

Proposed $400bn tie-up with Bristol Myers Squibb would create world’s fourth-largest drugmaker but analysts question rationale More than £17bn was wiped off the value of Britain’s...

AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress - Slideshow

<![CDATA[Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Col...

<![CDATA[CSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in China]]>

<![CDATA[Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report ]]>

<![CDATA[Pharmaceutical Executive Daily: AstraZeneca and Bristol Myers Squibb Held Merger Talks]]>

AstraZeneca shares rise as fresh reports deny mega-merger talks with US rival

Astra's stock climbed 2.5% or 296p to 12,036p after Reuters quoted a senior source at the business quashing rumours of any potential tie-up.

Attractive Growth Profile Positions AstraZeneca PLC (AZN) as Opportunity

AstraZeneca scores in lung cancer; Sandoz inks a China deal

A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism dr...

AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD

With a detailed data drop that AstraZeneca’s R&D chief describes as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it b...

AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up

Deal would create the world’s fourth-largest drugmaker by market value

New data could widen use of AstraZeneca, Amgen immune disease drug

Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.

ESC26: AstraZeneca's heart failure drug shows promise in ph. 2 trial

AstraZeneca’s oral relaxin agonist delivered encouraging phase 2b results in chronic heart failure, improving measures of cardiac function across two patient groups.

Astra takes £18bn hit as merger talks get a thumbs down: Analysts 'perplexed' by £300bn tie-up with US rival

The FTSE 100 firm's long-serving boss Pascal Soriot (pictured) is said to be intent on pushing ahead with the merger which could be announced as soon as today.

AstraZeneca Turns to China for Molecule That Might Top New Merck COPD Drug

AstraZeneca is getting rights to a Sino Biopharmaceutical drug that offers a dual mechanism to treat chronic obstructive pulmonary disease, or COPD. It’s the same approach as an FD...

HSBC downgrades AstraZeneca after key trial failure

AstraZeneca hit by lung cancer drug setback: Pharma giant halts trials of experimental Volrustomig treatment

Astra said its Volrustomig treatment, when combined with chemotherapy, was unlikely to help lung cancer patients live longer than rival offerings.